Cizzle Biotechnology plc (LON:CIZ), the UK based developer of a blood test for the early detection of a majority of the different forms of lung cancer, has announced the signing of
Cizzle Biotechnology’s Allan Syms discusses the MoU with St George Street Capital and what the company is looking to achieve over the coming months in this exclusive interview with DirectorsTalk.
Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk to discuss the signing of an MOU with St George Street Capital. Allan explains what a companion diagnostic is, what
Cizzle Biotechnology’s Allan Syms discusses what the company does, their patent portfolio, how they will use the funds raised and how they view the future for the company in this exclusive interview with DirectorsTalk.
Cizzle Biotechnology Holdings plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk to discuss the successful listing on to the Main Market of London Stock Exchange. Allan explains what the company
Cizzle Biotechnology Ltd (LON:CIZ) was identified by Bould Opportunities (Bould) as its preferred target for a reverse takeover. Cizzle is a spin-out from the University of York to exploit the
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
